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Background: A systematic review was conducted to assess the cost-effectiveness of routine varicella and herpes
zoster (HZ) vaccination in high-income countries estimated by modelling studies.
Methods: A PubMed search was performed to identify relevant studies published before October 2013. Studies
were included in the review if they (i) evaluated the cost-effectiveness of routine childhood or adolescent varicella
vaccination and/or HZ vaccination targeting the elderly, and if they (ii) reported results for high-income countries.
Results: A total of 38 model-based studies were identified that fulfilled the inclusion criteria. Routine childhood or
adolescent varicella vaccination was cost-effective or cost-saving from a payer perspective and always cost-saving
from a societal perspective when ignoring its potential impact on HZ incidence due to reduced or absent exogenous
boosting. The inclusion of the potential impact of childhood varicella vaccination on HZ led to net quality-adjusted
life-year (QALY) losses or incremental cost-effectiveness ratios exceeding commonly accepted thresholds. Additional
HZ vaccination could partially mitigate this effect. Studies focusing only on the evaluation of HZ vaccination reported
a wide range of results depending on the selected target age-group and the vaccine price, but most found HZ
vaccination to be a cost-effective or marginally cost-effective intervention. Cost-effectiveness of HZ vaccination was
strongly dependent on the age at vaccination, the price of the vaccine, the assumed duration of protection and the
applied cost per QALY threshold.
Conclusions: While HZ vaccination is mostly considered cost-effective, cost-effectiveness of varicella vaccination
primarily depends on the in- or exclusion of exogenous boosting in the model. As a consequence, clarification on the
role of exogenous boosting is crucial for decision-making regarding varicella vaccination.
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Primary infection with varicella-zoster virus (VZV) causes
varicella (chickenpox), which occurs mainly in childhood
[1, 2]. The virus persists lifelong in the dorsal roots of the
spinal and cranial ganglia. Later in life the virus can be
reactivated, manifesting as shingles (herpes zoster, HZ), a
painful skin rash that lasts approximately one month [1, 3].
The main complication of HZ is postherpetic neuralgia
(PHN), a long lasting neuropathic pain in the area
formerly affected by the HZ rash [3–6].* Correspondence: oliver.damm@uni-bielefeld.de
1Department of Health Economics and Health Care Management, Bielefeld
School of Public Health, Bielefeld University, Bielefeld, Germany
Full list of author information is available at the end of the article
© 2015 Damm et al. This is an Open Access a
(http://creativecommons.org/licenses/by/4.0),
provided the original work is properly credited
creativecommons.org/publicdomain/zero/1.0/Live-attenuated monovalent varicella vaccines or com-
bination vaccines against measles, mumps, rubella and
varicella (MMRV) licensed for use in children are avail-
able in most industrialised countries. As of today there
is one HZ vaccine licensed for individuals aged 50 years
and older.
Routine childhood varicella vaccination is generally
recommended in the United States, Australia, Canada,
Qatar, Saudi Arabia, Republic of Korea, Taiwan, Uruguay
and several countries in Europe including Germany,
Greece, Finland and parts of Italy and Spain [7, 8]. A sig-
nificant decline in varicella incidence was observed after
the introduction of routine vaccination in several coun-
tries [8–11]. Nationwide vaccination recommendationsrticle distributed under the terms of the Creative Commons Attribution License
which permits unrestricted use, distribution, and reproduction in any medium,
. The Creative Commons Public Domain Dedication waiver (http://
) applies to the data made available in this article, unless otherwise stated.
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individuals aged 50+ [12], the United States and in
Canada for individuals aged 60+ [13, 14] and in the UK
for individuals aged 70–79 [15].
In the 1960s, Hope-Simpson hypothesised that after
primary infection a re-exposure to wild-type VZV would
sub-clinically boost the individual’s VZV-specific im-
munity, thereby suppressing VZV reactivation and de-
creasing the probability of developing HZ [16]. Since
then, the hypothesis that HZ incidence will increase in a
population with routine varicella vaccination has been
discussed in the literature [17]. According to models,
varicella vaccination might lead to a substantial increase
in HZ incidence during approximately 40–50 years after
initiation of routine vaccination [18, 19]. In the United
States, where routine varicella vaccination was intro-
duced in 1995, studies monitoring HZ incidence have re-
ported inconsistent results until today [20]. However, a
more recent systematic review based on 39 multidisciplin-
ary studies concluded that exogenous boosting exists, but
its extent and public health impact remain unclear [21].
Our objective was to assess the cost-effectiveness of
routine varicella and HZ vaccination in high-income
countries estimated by modelling studies.
Methods
Search strategy
A PubMed search was performed to identify English-
and German-language articles on economic evaluations
of varicella and HZ vaccination published before October
2013. The systematic literature search was conducted
using the following key words: (varicella OR chickenpox
OR herpes zoster OR shingles OR varicella-zoster OR
VZV OR “Chickenpox” [MeSH] OR “Herpes Zoster”
[MeSH]) AND (vaccination OR vaccine OR vaccinating
OR vaccinate OR vaccinated OR immunisation OR immu-
nization OR “Vaccination” [MeSH] OR “Vaccine” [MeSH]
OR “Chickenpox Vaccine” [MeSH] OR “Herpes Zoster
Vaccine” [MeSH]) AND (economic OR economics OR
cost OR costs OR cost-effectiveness OR cost-effective OR
cost-utility OR cost-benefit OR benefit-cost OR cost-
saving OR pharmacoeconomic OR pharmacoeconomics
OR ICER OR QALY OR “Costs and Cost Analysis”
[MeSH]). Application of the non-MeSH search terms was
restricted to titles and abstracts of the PubMed records. In
addition, we screened reference lists of all included studies
to identify further articles of interest.
Study selection
Titles and abstracts of the obtained search results were
screened independently by two reviewers. Full-text ver-
sions of all potentially relevant studies were retrieved and
assessed according to pre-defined inclusion and exclusion
criteria by the same two reviewers. Any disagreementsbetween reviewers on inclusion of particular studies were
resolved by consensus. A study was included if it was a full
or partial economic evaluation of routine childhood (or
adolescent) varicella vaccination or a HZ immunisation
scheme targeting the elderly and if the modelling study re-
ported results for a high-income country as specified by
the World Bank (high-income OECD-members) [22].
Inclusion criteria related to comparators included no
vaccination as well as existing vaccination programmes or
private coverage. We did not define inclusion or exclusion
criteria related to outcome measures. We excluded non-
original research papers (i.e. review articles, letters, and
editorials), studies that focused on vaccination of specific
target groups (e.g. health care workers, adults without
history of chickenpox, transplant patients, seronegative
postpartum women, army recruits and cadets, immigrants
and refugees), studies that did not provide sufficient
details on the applied methods, studies that evaluated only
combined strategies of serotesting and vaccination as well
as studies that evaluated combination vaccines without
reporting separate results for each component.
Data extraction and synthesis
Critical appraisal of all included studies was undertaken
by using the framework for quality assessment of
decision-analytic models proposed by Philips et al. [23].
The quality assessment was performed by two independ-
ent reviewers. The framework used considers aspects
related to structure, data, and consistency of health eco-
nomic models. The following information was systematic-
ally extracted from each included study: citation details,
country, characteristics of the vaccination programme (e.g.
target age group, vaccine type, vaccine efficacy, vaccination
coverage), main features of the modelling approach (e.g.
model type, time horizon, interaction between varicella
and HZ), characteristics of the economic analysis (e.g. de-
termination of the perspective, choice of discount rate,
valuation of health gains), key findings as well as funding
sources. The economic value of routine varicella and HZ
vaccination was assessed by comparing incremental cost-
effectiveness ratios (ICERs) and/or benefit-cost ratios
(BCRs) among studies taking into account different im-
munisation strategies, perspectives as well as clinical and
epidemiological features of VZV.
To improve comparability between studies and across
countries, all cost estimates were inflated to 2010 values
(latest price year used in included studies) applying
country-specific consumer price indices and converted
to Euros with the German level of purchasing power
using purchasing power parities obtained from the Or-
ganisation for Economic Co-operation and Development
(OECD) [24].
The reporting of this systematic review was performed
in accordance with the PRISMA statement [25]. However,
Damm et al. BMC Public Health  (2015) 15:533 Page 3 of 19not all items of the PRISMA statement checklist are ap-
plicable to economic evaluations.
Results
Search results and quality assessment
The literature search in PubMed identified 351 articles.
After screening the titles and abstracts of these hits, 92
papers were considered for full-text review. 41 papers of
the obtained full-text articles met the inclusion criteria.
The main reasons for exclusion were incorrect type of
study (such as review articles), incorrect intervention or
studies assessing the vaccination of specific target groups.
Few studies were excluded due to insufficient information
on the methods used. Four of the 41 papers that met the
inclusion criteria reported on the same modelling study
and three of them were therefore excluded. Finally, 38
studies were included in the review. A flow chart of the
study selection process and the corresponding results is
outlined in Fig. 1.
Most of the included studies were of high quality.
However, some studies evaluating varicella vaccination
did not use a dynamic modelling approach and hence
are not able to capture indirect effects of vaccination.
Most studies performed probabilistic sensitivity analysis
to address the issue of parameter uncertainty, but only a
few studies evaluated the impact of structural uncertain-
ties. Several studies also lack detailed descriptions/dis-
cussion of the sources of utility weights.Fig. 1 Flow chart of study selection processStudy characteristics
Varicella vaccination
We included 23 model-based studies evaluating the
cost-effectiveness of routine varicella vaccination. Table 1
gives an overview of general study characteristics and in-
formation on the applied modelling framework of these
studies. The majority of the studies was performed for
European countries.
13 studies used a fully dynamic modelling approach in
terms of simulating the transmission dynamics of vari-
cella. 10 studies were based on static models. By defin-
ition, all dynamic models accounted for herd protection
effects. The static model from Israel reported to have in-
cluded partial herd protection effects by use of an adjust-
ment factor. Apart from herd protection effects, varicella
immunisation programmes can induce other population-
level effects such as the hypothesised increase in HZ inci-
dence due to a reduced or absent exogenous boosting
after varicella vaccine introduction and subsequent de-
crease in wild virus circulation in the population. Most of
the models ignored the close relationship between vari-
cella and HZ. Only four studies modelled the possible im-
pact of routine varicella vaccination on HZ incidence in a
population due to a decrease in wild-type VZV circulation.
Many studies performed a cost comparison analysis
and reported the results as BCRs. Some of these studies
claimed to have conducted a cost-benefit analysis but this
would require a monetary valuation of health effects.
Table 1 General study characteristics of the models evaluating routine varicella vaccination
Study Country Model
type
Accounting
for herd
protection
Impact of varicella
vaccination on
HZ incidence
Time
horizon
Type of
economic
evaluation
Perspective Discount rate
(costs/health
effects)
Costing year
and currency
Funding
source
Banz et al. [35] Germany Dynamic Yes No 30 years CC Health care payer; societal 5 %/0 % 1999 EUR Industry
Banz et al. [51] Switzerland Dynamic Yes No 30 years CC; CEA Health care payer; societal 5 %/0 % 2008 CHF Industry
Beutels et al. [37] Germany Static No No 70 years CC; CEA Health care payer; societal 5 %/5 % 1995 DEM Independent
Bilcke et al. [30] Belgium Dynamic Yes Depending on the
type of analysis
Various CEA; CUA Health care payer 3 %/1.5 % 2010a EUR Independent
Bonanni et al. [36] Italy Dynamic Yes No 30 years CC Health care payer; societal 3 %/0 % 2007a EUR Industry
Brisson et al. [31] Canada Dynamic Yes Yes (only in a
separate analysis)
30 years CC; CEA Health care payer; societal 3 %/3 % 1997/1998 CAD Independent
Brisson et al. [32] England and Wales Dynamic Yes Yes 80 years CUA Health care payer; societal 3 %/3 % 2001 GBP Independent
Coudeville et al. [52] France Dynamic Yes No 30 years CC Health care payer; societalb 5 %/NA 1995 FRF Industry
Coudeville et al. [53] Italy Dynamic Yes No 50 years CC Health care payer; societal 3 %/NA 2002 EUR Industry
Coudeville et al. [54] France and Germany Dynamic Yes No 50 years CC; CEA Health care payer; societal 3 %/3 % 2002 EUR Industry
Diez Domingo et al. [55] Spain Static No No 20 years CC Health care payer; societal 5 %/NA 1994 PTA Independent
Getsios et al. [56] Canada Static No No 70 years CEA; CUA Health care payer; societal 3 %/3 % 1998 CAD Independent
Ginsberg & Somekh [57] Israel Static Partially No Lifetime CC Health care payer; societal 3 %/NA 2002 USD Independent
Hammerschmidt et al. [58] Germany Dynamic Yes No 30 years CC Health care payer; societal Not specified
(probably 5 %
for costs)
1999/2006c EUR Industry
Huse et al. [59] USA Static No No 24 years CC Societal 5 %/5 % 1991 USD Industry
Lenne et al. [60] Spain Dynamic Yes No 50 years CC; CEA Health care payer; societal 3 %/0 % 2004 EUR Industry
Lieu et al. [61] USA Dynamic Yes No 30 years CC; CEA Health care payer; societal 5 %/5 % 1990 USD Independent
Preblud et al. [62] USA Static No No 30 years CC Health care payer; societal 5 %/0 % 1984 USD Independent
Scuffham et al. [63] New Zealand Static No No 30 years CC Health care payer; societal 5 %/5 % 1997 NZD Industry
Scuffham et al. [34] Australia Static No No 30 years CEA Health care payer 5 %/5 % 1996/1997 AUD Independent
Thiry et al. [64] Italy Static No No 100 years CC; CEA Health care payer; societal 3 %/3 % 2002 EUR Industry
van Hoek et al. [33] UK Dynamic Yes Yes Infinite CUA Health care payer 3.5 %/3.5 % 2007 GBP Independent
Zhou et al. [29] USA Static No No Lifetime CC; CUA Health care payer; societal 3 %/3 % 2006 USD Industry
CC cost-comparison; CEA cost-effectiveness analysis; CUA cost-utility analysis; NA = not applicable
aAssumption
bIndirect costs were not evaluated in monetary terms but reported as the number of days of absence from work
cPersonal communication with the author (1999 prices; 2006 vaccine prices)
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comparison analyses only considered costs and cost offsets
instead of valuing health effects in monetary terms.
Most of the studies adopted both a health care payer
and a societal perspective. Costs were discounted with a
discount rate ranging from 3 to 5 %. The discount rate for
health effects ranged from 0 to 5 %. Vaccination costs var-
ied widely across studies. The simulated time horizons
ranged from 20 years to a lifetime or an infinite time hori-
zon, but most studies used a period of 30 or 50 years.
Aspects related to vaccine characteristics and immun-
isation strategies considered in the included studies are
presented in Table 2. The majority of the studies com-
pared universal vaccination to a situation without vaccin-
ation. Few studies chose an existing one-dose varicella
vaccination programme or a situation with low private
vaccination coverage as comparator. While most of the
studies considered a 1-dose vaccination schedule, some
studies also (or exclusively) assessed the impact of two
varicella vaccine doses. Considered vaccine efficacy ranged
from 80 to 97 % and from 93 to 96 % for the first and the
second dose, respectively. Waning of vaccine-induced im-
munity was modelled in very different ways. Some models
did not consider waning immunity at all; other models
used yearly waning rates of 0.5 or 3.1 %. A UK study used
various waning rates ranging from 0.05 to 6.7 %. Some
studies stated that waning was applied to 15 % of the pro-
tected vaccinees without quantifying the waning rate per
year. Assumed vaccination coverage in the models ranged
from 30 to 97.15 %. Most of the studies included a fee for
administering the vaccine. Some studies included add-
itional costs for treating adverse events and/or costs of
vaccine wastage.
Herpes zoster vaccination
We included 17 model-based studies evaluating the cost-
effectiveness of HZ vaccination. The main study character-
istics are summarised in Table 3. We identified 15 studies
which considered the health economic impact of HZ vac-
cination exclusively. The remaining two studies considered
both varicella and HZ vaccination. Most studies were
conducted for European countries. The two studies target-
ing varicella as well as HZ vaccination applied a dynamic
modelling approach. One study used a discrete-event
simulation model that simulated individual patients [26].
All other cost-effectiveness studies were based on static
(Markov) state-transition models or similar models using
single or multiple cohorts. However, the number of in-
cluded disease states differed among models. While most
models considered common states like healthy, HZ, PHN,
and death, four studies included also different pain levels
(mild, moderate and severe) for HZ and PHN. Some stud-
ies failed to report explicit information on the modelled
health states or their number.All studies conducted a cost-utility analysis (CUA).
Furthermore, almost half of the studies also performed a
cost-effectiveness analysis (CEA). According to respect-
ive national guidelines, six studies used different dis-
count rates for costs and health effects. One study used
equal discount rates for costs and health effects that
changed over time following the current French guide-
lines: A 4 % discount rate was used for the first 30 years
of the model run and afterwards the discount rate was
reduced to 2 %. Most studies used a lifetime horizon.
Details of the HZ vaccination-related input data are
shown in Table 4. All models compared a vaccination
scenario with no vaccination. Vaccine efficacy estimates
were mostly based on clinical trial data of the Shingles
Prevention Study [27]. Several studies neglected waning
of vaccine-induced immunity in the base-case analysis.
The age at vaccination varied between 50 and 80 years.
Six studies did not report the assumed vaccination
coverage. However, in static models vaccination costs
and effects are proportional to vaccination coverage and
hence the level of coverage has no impact on the ICER.
A wide range of vaccination costs was applied across
the studies. One study [28] considered vaccination costs
between EUR 43.85 and 438.46 per dose in multiple sce-
narios, while the vaccination costs among the other
studies ranged from EUR 81.54 to 147.48 per dose or
per immunisation course. Thirteen studies included ad-
ministration fees in these cost estimates. One study in-
cluded additional costs for a public awareness campaign,
patient time costs, and costs for treating adverse events.
Results of the included studies
Varicella vaccination
The results of economic evaluations of varicella vaccin-
ation are summarised in Table 5. BCRs for one-dose
varicella vaccination of young children ranged between
0.30 and 1.94 when taking a health care payer perspective
and ignoring a potential impact on HZ. Six studies re-
ported BCRs above 1 or stated that vaccination would lead
to cost-savings. Eleven studies reported BCRs below 1 or
calculated ICERs. In these studies, costs per life year
gained (LYG) ranged between EUR 563 and EUR 40,193.
One study reported a BCR of 1 which means that one-
dose varicella vaccination was a cost-neutral intervention
[29]. When adopting a societal perspective and ignoring a
potential impact on HZ, all studies found that one-dose
varicella vaccination of toddlers and young children would
be cost-saving with BCRs ranging from 1.61 to 19.33.
BCRs for two dose-vaccination targeting young chil-
dren ranged between 0.13 and 1.08 when adopting a health
care payer perspective and between 0.56 and 3.47 when
taking a societal perspective. The study by Bilcke et al. [30]
reported ICERs below EUR 35,000 per QALY for a two
dose-vaccination scheme from a payer perspective when
Table 2 Vaccine characteristics and immunisation strategies considered in the models evaluating routine varicella vaccination
Study Age at vaccination Vaccine efficacy Waning (per year) Vaccination cov ge Vaccination costs per dose
(2010 EUR; German price level)
Banz et al. [35] 15 months; 11–12 years 86 % 0.5 % 85 % (children); %
(adolescents)
EUR 65.93 (children)a;
EUR 71.38 (adolescents)a
Banz et al. [51] 1-2 years; 11–15 years 95 % 0.5 % 70 % (children); %
(adolescents)
EUR 42.20 (children)a;
EUR 56.65 (adolescents)a
Beutels et al. [37] 15 months; 12 years 90 % Waning in 15 % of the
protected vaccineesb
70 % EUR 50.82a
Bilcke et al. [30] 1 year (1st dose); 4, 6 or
11 years (2nd dose)
Data from van Hoek
et al. 2012
Data from van Hoek
et al. 2012
50 % or 95 % (1 dose);
50 %, 80 % or 9
(2nd dose)
EUR 44.92a
Bonanni et al. [36] 12-18 months; 13 years 90 % (1st dose);
93 % (2nd dose)
3 % 85 % EUR 46.81a,c
Brisson et al. [31] 12 months; 12 years 93 % 3.1 % 90 % (infants); 8 %
(adolescents)
EUR 51.42 (children)a;
EUR 68.57 (adolescents)a
Brisson et al. [32] Infants; 11 years 93 % 3.1 % 90 % (infants); 8 %
(adolescents)
EUR 44.32 (children)a;
EUR 59.10 (adolescents)a
Coudeville et al. [52] <6 years 90 % Waning in 15 % of the
protected vaccineesb
80 % EUR 18.11c,d
Coudeville et al. [53] 12-36 months 97 % 3.1 % 45 %-90 % EUR 52.00a,c
Coudeville et al. [54] 12-36 months 97 % 3.1 % 45 %-90 % EUR 64.08 (Germany)a,c;
EUR 59.56 (France)a,c
Diez Domingo et al. [55] 15 months 90 % No waning 95 % EUR 37.11
Getsios et al. [56] 12 months 90 % Waning in 15 % of the
protected vaccineesb
85 % EUR 60.25a,d
Ginsberg & Somekh [57] 12 months 87.6 % 3.1 % 94 % EUR 8.01a,c,d
Hammerschmidt et al. [58] 11-23 months
(catch-up of 2–17 year olds)
86 % (1-dose schedule);
95 % (2-dose schedule)
0.5 % 90 % (1st dose) %
(2nd dose); 30 % catch-up);
10 % (comparat )
EUR 47.38 (monovalent vaccine);
EUR 47.92 (varicella-attributable
cost of the MMRV vaccine)
Huse et al. [59] 15 months 95 % No waning Not specified EUR 62.31a
Lenne et al. [60] 1-2 years 97 % 3,1 % 97,15 % EUR 42.54a
Lieu et al. [61] <6 years 90 % Waning in 15 % of the
protected vaccineesb
97 % EUR 54.12a
Preblud et al. [62] 15 months 90 % No waning 90 % EUR 25.53
Scuffham et al. [63] 15 months 95 % No waning 80 %; 10 % (com arator) EUR 45.94
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Table 2 Vaccine characteristics and immunisation strategies considered in the models evaluating routine varicella vaccination (Continued)
Scuffham et al. [34] 12 months; 12 years 95 % No waning 80 % (infants); 50-75 %
(adolescents)
EUR 42.26
Thiry et al. [64] 11 years 93,12 % 3.1 % 60 % EUR 52.36a
van Hoek et al. [33] 1 year (1st dose);
3 years (2nd dose)
89-96 % (1st dose);
93-96 % (2nd dose)
1.5-6.7 % (1st dose);
0.05-2.6 % (2nd dose)
90 % (1st dose);
80 % (2nd dose)
EUR 41.19
Zhou et al. [29] Children 80 % (1-dose schedule)e;
93 % (2-dose schedule)
No waning Age-specific coverage rates;
95 % (2nd dose)
EUR 49.90 (monovalent vaccine)f;
EUR 65.64 (MMRV vaccine)f
MMRV measles, mumps, rubella and varicella
aIncluding administration costs
bWaning rate per year not quantified
cIncluding costs of treating adverse events
dIncluding vaccine wastage
eThis efficacy estimate was not directly used in the model; the vaccine-induced reduction in incidence was calculated by using age-specific surveillance data
fPublic sector price
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Table 3 General study characteristics of the models evaluating routine HZ vaccination
Study Country Model
type
Time horizon Type of
economic
evaluation
Perspective Discount rate
(costs/health effects)
Costing year
and currency
Funding source
Annemans et al. [65] Belgium Static Lifetime CEA; CUA Health care payer
(with and without co-payments); societal
3 %/1.5 % 2007 EUR Industry
Bilcke et al. [38] Belgium Static Lifetime CEA; CUA Health care payer 3 %/1.5 % 2009a EUR Independent
Bilcke et al. [30] Belgium Dynamicb Various CEA; CUA Health care payer 3 %/1.5 % 2011a EUR Independent
Bresse et al. [66] France Static Lifetime CEA; CUA Health care payer
(with and without co-payments)
4 %/4 %c 2010 EUR Industry
Brisson et al. [67] Canada Static Lifetime CUA Health care payer 5 %/5 % 2005 CAD Industry
de Boer et al. [40] Netherlands Static Up to 41 years CUA Health care payer; societal 4 %/1.5 % 2010 EUR Independent
Edmunds et al. [68] England and Wales Static Lifetime CEA; CUA Health care payer 3 %/3 % 1998 GBP Independent
Hornberger et al. [28] USA Static 30 years CUA Societal 3 %/3 % 2006 USD Independent
Moore et al. [69] UK Static Lifetime CEA; CUA Health care payer; societal 3.5 %/3.5 % 2006 GBP Industry
Najafzadeh et al. [26] Canada Static Lifetime CUA Health care payer 5 %/5 % 2008 CAD Independent
Pellissier et al. [70] USA Static Lifetime CUA Health care payer; societal 3 %/3 % 2006 USD Industry
Rothberg et al. [42] USA Static Not specified CUA Societal 3 %/3 % 2005 USD Independent
Szucs et al. [71] Switzerland Static Lifetime CEA; CUA Health care payer; societal 3.5 %/1.5 % 2010a CHF Industry
Ultsch et al. [39] Germany Static Lifetime CEA; CUA Health care payer; societal 3 %/3 % 2010 EUR Independent
van Hoek et al. [72] England and Wales Static Lifetime CUA Health care payer 3.5 %/3.5 % 2006 GBP Independent
van Hoek et al. [33] UK Dynamicb Infinite CUA Health care payer 3.5 %/3.5 % 2007 GBP Independent
van Lier et al. [41] Netherlands Static Not specified CUA Health care payer; societal 4 %/1.5 % 2008 EUR Independent
CEA cost-effectiveness analysis; CUA cost-utility analysis
aPersonal communication with the author or assumption
bCombined evaluation of varicella and HZ vaccination
cDiscount rate for costs and health effects was reduced to 2 % after 30 years
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Table 4 Vaccine characteristics and immunisation strategies considered in the models evaluating routine HZ vaccination
Study Age at vaccination
(in years)
Vaccine efficacy against HZ Waning or duration of protection Vaccination
coveragea
Vaccination costs
per dose (2010 EUR,
German price level)
Annemans et al. [65] 50+ 37.6-63.9 %, age-dependent No waningb 20 % EUR 141.39c
Bilcke et al. [38] 60-85 Age-dependent (values are reported graphically only) Consideration of waning depends on the choice
of scenario
30 % EUR 106.95d
Bilcke et al. [30] 50 or 60 77 %e Duration of protection of 7.5 years or
lifelong protection
30 % or 70 % EUR 103.38d
Bresse et al. [66] 65+ 18-64 %, age-dependent 4.15 % per year and vaccine efficacy was set to zero
after 10 years
20 % EUR 117f
Brisson et al. [67] 50-80 26-75 %, age-dependent No waningb Not specified EUR 108.60
de Boer et al. [40] 60-75 41.2-69.4 %, age-dependent 8.3 % per year (= duration of protection of 12 years) Not specified EUR 89.10d
Edmunds et al. [68] 65 30-70 % Duration of protection of 2.5 years to life long 60 % EUR 122.13d,g
Hornberger et al. [28] 69 Modelled by applying age-specific incidence of HZ
in vaccine and placebo-treated arm of the clinical
study, age-dependent
Duration of protection of 30 years Not specified EUR 43.85-438.46d,h
Moore et al. [69] 50+ 37.6-63.9 %, age-dependent No waningb 40 % EUR 143.28d
Najafzadeh et al. [26] 60+ Modelled by applying age-specific incidence of HZ
in vaccine and placebo-treated arm of the clinical
study, age-dependent
4.5 % per year Not specified EUR 101.83
Pellissier et al. [70] 60+ 27.1-69.8 %, age-dependent No waningb Not specified EUR 147.32d
Rothberg et al. [42] 60-80 Age-dependent Waning considered but not quantified Not specified EUR 134.74d
Szucs et al. [71] 70-79 37.60-63.9 %, age-dependent No waningb 20 % EUR 143.09d
Ultsch et al. [39] 50-80 13.22-69.8 %, age-dependent 8.3 % per year following 10 years of stable
vaccine efficacy
20 % EUR 147.48d
van Hoek et al. [72] 60-75 31-95 % (based on 15 different take and waning scenarios),
age-dependent
Duration of protection of 3.6-100 years
(based on 15 different take and waning scenarios)
73.5 % EUR 88.36d
van Hoek et al. [33] 75 Data from van Hoek et al. [72] Data from van Hoek et al. [72] 70 % EUR 86.37d
van Lier et al. [41] 60-80 Data from van Hoek et al. [72] Duration of protection of 7.5 years 75 % EUR 81.54d
HZ herpes zoster
aIn static models vaccination costs and effects are proportional to vaccination coverage. Hence, the level of coverage has no impact on the incremental cost-effectiveness ratio
bBase-case analysis
cIncluding co-payments
dIncluding administration costs
eThis value was assumed for the age group of 60–64 years. The supplemental material of this study also provides values for higher age groups (7-68 %) but no estimate is given for the age group below 60 years
fReimbursement rate was assumed to be 65 % when taking a third-party payer perspective
gCosts of an immunisation course comprising two doses
hIncluding public awareness campaign, patient travel time, time receiving vaccine and costs of treating adverse events
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Table 5 Economic results of the models evaluating routine varicella vaccination (2010 EUR, German price level)
Study Age at vaccination Dose
schedule
Comparator Health care payer perspective Societal perspective
Banz et al. [35] 15 months 1 No vaccination BCR 1.75 BCR 4.12
11-12 yearsa 1 No vaccination BCR 1.13 BCR 8.44
combined 1 No vaccination BCR 1.70 BCR 4.10
Banz et al. [51] 1-2 years 2 2-dose vaccination
at 11–15 yearsa
BCR 0.30; EUR 856/LYG BCR 1.29
Beutels et al. [37] 15 months 1 No vaccination BCR 0.82; EUR 14,700/LYG BCR 4.60
12 yearsa 1 No vaccination BCR 1.94 BCR 6.02
Bilcke et al. [30] 1 year (95 % coverage) 1 No vaccination EUR 550–14,140/QALY NA
1 year (1st dose, 95 % coverage);
4 years (2nd dose, 90 % coverage)
2 No vaccination EUR 5,240-31,942/QALY NA
1 year (1st dose, 95 % coverage);
11 years (2nd dose, 80 % coverage)
2 No vaccination EUR 5,043-29,775/QALY NA
1 year (1st dose, 50 % coverage);
4 years (2nd dose, 50 % coverage)
2 No vaccination EUR 3,345-23,240/QALY NA
All vaccination options (including and
excluding additional HZ vaccination)
2 No vaccination Net QALY loss for many time horizonsb;
EUR 36,256-135,961/LYGb
NA
Bonanni et al. [36] 12-18 months 2 No vaccination BCR 0.67 BCR 3.47
13 years 2 No vaccination BCR 0.36 BCR 2.60
Brisson et al. [31] 12 months 1 No vaccination BCR 0.61; EUR 38,142/LYG BCR 5.24
12 months 1 No vaccination BCR 0.59c; EUR 40,193/LYGc BCR 5.09c
12 months 1 No vaccination BCR 0.16b; EUR 101,296/LYGb NA
12 yearsa 1 No vaccination BCR 0.73; EUR 15,863/LYG BCR 4.44
Brisson et al. [32] Infants 1 No vaccination Net QALY lossb Net QALY lossb
11 yearsa 1 No vaccination EUR 26,110/QALYb Cost-savingb
Coudeville et al. [52] <6 years 1 No vaccination Net benefit EUR 326.8 million NA
Coudeville et al. [53] 12-36 months 1 No vaccination BCR 1.20 at high vaccination coverage BCR 3.50 at high
vaccination coverage
Coudeville et al. [54] 12-36 months 1 No vaccination Cost-saving at high vaccination coverage
(Germany 51 %; France 6.7 %); EUR 6.960/LYG
at low vaccination coverage
(France; cost-saving in Germany)
Cost-saving at high
vaccination coverage
(Germany 61 %; France 60 %)
DIez Domingo et al. [55] 15 months 1 No vaccination BCR 0.54 BCR 1.61
Getsios et al. [56] 12 months 1 No vaccination EUR 71,722/QALY; EUR 36/varicella case avoided Cost-saving
Ginsberg & Somekh [57] 12 months 1 No vaccination BCR 1.63 BCR 19.33
Hammerschmidt et al. [58] 11-23 months (including a catch-up
of 2–17 year oldsa)
2 (1 dose
for catch-up)
1-dose vaccination
at 12–15 yearsa
BCR 1.08 BCR 2.56
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Table 5 Economic results of the models evaluating routine varicella vaccination (2010 EUR, German price level) (Continued)
Huse et al. [59] 15 months 1 No vaccination NA Cost-saving (net benefit
of EUR 86.28 per vaccinee)
Lenne et al. [60] 1-2 years 1 No vaccination BCR 0.91; EUR 5,202/LYG BCR 3.70
Lieu et al. [61] <6 years 1 No vaccination BCR 0,90; EUR 21,648/LYG; EUR 5.68/varicella
case prevented
BCR 5.40
Preblud et al. [62] 15 months 1 No vaccination BCR 0.30 BCR 6.90 (including home
care costs)
Scuffham et al. [63] 15 months 1 No routine vaccination
but low private coverage
BCR 0.67 BCR 2.79
Scuffham et al. [34] 12 months 1 No vaccination EUR 49.11/varicella case avoided;
EUR 16,439/hospitalisation avoided
NA
12 yearsa 1 No vaccination EUR 404.81/varicella case avoided;
EUR 26,791/hospitalisation avoided
NA
Thiry et al. [64] 11 yearsa 1 No vaccination BCR 0.54; EUR 26,988/LYG BCR 2.17
van Hoek et al. [33] 1 year (first dose); 3 years (second dose) 2 No vaccination 41 % of the simulations below GBP 20,000/QALY
(EUR 26,576/QALY)b; 50 % of the simulations
below GBP 30,000/QALY (EUR 39,864/QALY)b
NA
1 year (first dose); 3 years (second dose) +
HZ vaccination of the elderly
2 No vaccination 50 % of the simulations below GBP 20,000/QALY
(EUR 26,576/QALY)b; 70 % of the simulations
below GBP 30,000/QALY (EUR 39,864/QALY)b
NA
Zhou et al. [29] Children 1 No vaccination BCR 1.00 BCR 4.37
Children 2 No vaccination BCR 0.61 BCR 2.73
Children 2 1-dose vaccination BCR 0.13 BCR 0.56; EUR 95,584/QALY
BCR benefit-cost ratio; LYG life-year gained; QALY quality-adjusted life-year; NA not applicable
aWith a negative or uncertain history of varicella
bIncluding the impact on HZ
cIncluding the impact of breakthrough varicella
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study found that a two-dose vaccination regime would be
less cost-effective than a single-dose childhood vaccin-
ation strategy. Beyond that, the study by Zhou et al. [29]
showed that the choice of the comparator was very influ-
ential when evaluating two-dose varicella vaccination. In
the study by Bilcke et al. [30] a two-dose vaccination strat-
egy led to more cost-effective results at lower (50 %) than
at higher vaccination coverage (round 90 %) due to the
development of herd protection effects.
The inclusion of the impact on HZ incidence led to
less cost-effective results. Brisson et al. [31] found an
ICER of EUR 101,296 per LYG (health care payer per-
spective) when evaluating one-dose vaccination for tod-
dlers in Canada. Adopting a similar approach for
England and Wales, Brisson et al. [32] found a net
QALY-loss. In another study from the UK [33], which
focused on a 2-dose schedule, 50 % of the simulations
exceeded a threshold of GBP 30,000 per QALY (EUR
39,864 per QALY). Bilcke et al. [30] concluded that a
childhood vaccination programme is not expected to be
cost-effective for several decades when assuming ex-
ogenous boosting.
BCRs of vaccinating young adolescents ranged be-
tween 0.36 and 1.94 from a health care payer perspec-
tive. ICERs were EUR 15.863 per LYG [31], EUR 26,110
per QALY [32] and EUR 26,791 per hospitalisation
avoided [34]. Compared to cost-effectiveness estimates
of routine childhood varicella vaccination, two studies
showed that adolescent vaccination strategies might be
less cost-effective than targeting toddlers [35, 36], while
other studies found contrary results [31, 32, 34, 37]. The
inclusion of indirect costs (societal perspective) im-
proved the BCRs as it was found with the toddler vac-
cination strategies.
Herpes zoster vaccination
The results of models assessing the cost-effectiveness of
HZ vaccination are shown in Table 6. One study [38] re-
ported cost-effectiveness results for scenarios most and
least in favour of vaccination instead of reporting results
of a base-case analysis. Hence, the results of this study
comprised a wide range of estimates ranging from EUR
1,200 to 291,240 per QALY (payer perspective). When
considering a payer perspective, ICERs among all other
studies ranged from EUR 5,412 to 140,125 per QALY.
However, the majority of studies reported ICERs from
EUR 10,000 to 40,000 per QALY. In terms of costs per
HZ case avoided, ICERs varied from EUR 584 to 42,164
in the study from Bilcke et al. [38] and from EUR 817 to
9,433 in other studies when adopting a payer perspec-
tive. Few studies also reported ICERs in terms of costs
per PHN-case avoided, which ranged from EUR 2,936 to
35,717 (payer perspective).When taking a societal perspective, one US study [28]
reported a wide range of results ranging from cost-
saving to EUR 250,470 per QALY. Results of other stud-
ies varied from EUR 5,628 to 173,224 per QALY.
Several studies, which included waning of vaccine-
induced immunity and reported results for different ages
at vaccination identified an U-shaped figure of vaccination
age-related ICERs: Cost-effectiveness ratios decreased
with increasing age at vaccination up to the age of 60
or 70 years and then increased with further increase in
age at vaccination. In addition, many studies reported
that cost-effectiveness was highly dependent on the as-
sumed duration of vaccine-induced protection and the
price of the vaccine. Particularly, the study by Hornberger
et al. [28] showed how strongly ICERs can be affected
by changes in duration of protection and vaccine cost.
Ultsch et al. [39] also found a considerable impact
when exploring the combined influence of varying
waning immunity rates and durations of stable vaccine
efficacy.
The majority of the included studies concluded that HZ
vaccination would represent a cost-effective strategy. How-
ever, some studies came to different conclusions, mostly
due to the application of different cost-effectiveness
thresholds. The authors of a Dutch study [40] concluded
that HZ vaccination might be cost-effective when using a
threshold of EUR 50,000 per QALY, but not when decreas-
ing the threshold to EUR 20,000 per QALY. Another study
from the Netherlands [41] also reported ICERs above EUR
20,000 per QALY. The authors of this study concluded
that HZ vaccination at the age of 70 years is expected to
be marginally cost-effective. Hornberger et al. [28] were
very cautious in deriving clear conclusions because of the
high uncertainty around the cost-effectiveness results. The
same applies to the US study by Rothberg et al. [42]. They
found that ICERs often exceeded USD 100,000 (EUR
80,000-90,000) per QALY.
Combined varicella and herpes zoster vaccination strategy
Two studies [30, 33] modelled the cost-effectiveness of a
combined varicella and HZ vaccination strategy (Table 5).
The UK study [33] found that 70 % of the simulations lay
below GBP 30,000 (EUR 39,864) per QALY when taking
an infinite time horizon. Without the HZ vaccination
component this fraction of simulations decreased to 50 %.
According to the authors, the combined strategy is likely
to be the optimum strategy, but results were highly sensi-
tive with regard to the applied time frame. For example,
when adopting time horizons of 30 to 50 years, there was
a high probability that the combined strategy would not
be cost-effective. The Belgium model adaptation [30],
which was based on the previously mentioned UK model,
predicted that a combined vaccination strategy would lead
to a net QALY loss for many time horizons.
Table 6 Economic results of the models evaluating HZ vaccination in the elderly (2010 EUR, German price level)
Study Age at vaccination (years) Comparator Health care payer perspective Societal perspective
Annemans et al. [65] 50+ No vaccination EUR 6,624/QALY; EUR 1,046/HZ case avoided;
EUR 3,495-3,523/PHN case avoideda
EUR 6,822/QALY; EUR 1,077/HZ case avoided;
EUR 3,600-3,629/PHN case avoideda
60+ No vaccination EUR 6,809/QALY; EUR 1,310/HZ case avoided;
EUR 3,942-3,969/PHN case avoideda
EUR 7,148/QALY; EUR 1,375/HZ case avoided;
EUR 4,039-4,137/PHN case avoideda
65+ No vaccination EUR 7,184/QALY; EUR 1,560/HZ case avoided;
EUR 4,176-4,336/PHN case avoideda
EUR 7,577/QALY; EUR 1,645/HZ case avoided;
EUR 4,404-4,574/PHN case avoideda
60-64 No vaccination EUR 5,694/QALY; EUR 817/HZ case avoided;
EUR 2,936-2,969/PHN case avoideda
EUR 5,867/QALY; EUR 842/HZ case avoided;
EUR 3,025-3,059/PHN case avoideda
65-69 No vaccination EUR 5,412/QALY; EUR 873/HZ case avoided;
EUR 2,967-2,991/PHN case avoideda
EUR 5,628/QALY; EUR 909/HZ case avoided;
EUR 3,087-3,112/PHN case avoideda
60-69 No vaccination EUR 5,553/QALY; EUR 844/HZ case avoided;
EUR 2,951-2,980/PHN case avoideda
EUR 5,747/QALY; EUR 874/HZ case avoided;
EUR 3,054-3,085/PHN case avoideda
Bilcke et al. [38] 60 No vaccination EUR 1,200-46,968/QALY;
EUR 584–5,148/HZ case avoided
NA
70 No vaccination EUR 2,200-70,496/QALY;
EUR 1,239-8,603/HZ case avoided
NA
80 No vaccination EUR 3,824-126,793/QALY;
EUR 2,867-17,353/HZ case avoided
NA
85 No vaccination EUR 5,272-291,240/QALY;
EUR 4,451-42,164/HZ case avoided
NA
Bilcke et al. [30] 50 or 60 No vaccination No results for a sole HZ vaccination reported;
see Table 5 for results on combined varicella
and HZ vaccination
NA
Bresse et al. [66] 65+ No vaccination EUR 11,480/QALY; EUR 2,479/HZ case avoided;
EUR 4,101/PHN case avoidedb
NA
70-79 No vaccination EUR 8,876/QALY; EUR 2,090/HZ case avoided;
EUR 3,302/PHN case avoidedb
NA
Brisson et al. [67] 50 No vaccination EUR 36,667/QALY NA
60 No vaccination EUR 26,563/QALY NA
65 No vaccination EUR 24,002/QALY NA
70 No vaccination EUR 22,924/QALY NA
80 No vaccination EUR 33,153/QALY NA
de Boer et al. [40] 60 No vaccination EUR 40,050/QALY EUR 33,901/QALY
65 No vaccination EUR 34,440/QALY EUR 33,511/QALY
70 No vaccination EUR 28,491/QALY EUR 28,284/QALY
75 No vaccination EUR 28,506/QALY EUR 28,506/QALY
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Table 6 Economic results of the models evaluating HZ vaccination in the elderly (2010 EUR, German price level) (Continued)
Edmunds et al. [68] 65 No vaccination EUR 5,435-100,700/QALYc NA
Hornberger et al. [28] 69 No vaccination NA From cost-saving up to EUR 250,470/QALYd
Moore et al. [69] 50+ No vaccination EUR 17,681/QALY; EUR 1,957/HZ case avoided;
EUR 7,369-7,413/PHN case avoided
EUR 15,520/QALY; EUR 1,710/HZ case avoided;
EUR 6,434-6,472/PHN case avoided
50-54 No vaccination EUR 18,041/QALY EUR 12,488/QALY
55-59 No vaccination EUR 16,182/QALY EUR 12,124/QALY
60-64 No vaccination EUR 14,931/QALY EUR 12,866/QALY
65-69 No vaccination EUR 13,967/QALY EUR 13,638/QALY
70-74 No vaccination EUR 17,814/QALY EUR 17,814/QALY
75-79 No vaccination EUR 20,352/QALY EUR 20,352/QALY
80-84 No vaccination EUR 27,176/QALY EUR 27,176/QALY
85-89 No vaccination EUR 45,799/QALY EUR 45,799/QALY
90-94 No vaccination EUR 67,522/QALY EUR 67,522/QALY
95-99 No vaccination EUR 100,562/QALY EUR 100,562/QALY
100+ No vaccination EUR 140,125/QALY EUR 140,125/QALY
Najafzadeh et al. [26] 60+ No vaccination EUR 28,314/QALY NA
60-74 No vaccination EUR 24,002/QALY NA
75+ No vaccination EUR 44,123/QALY NA
Pellissier et al. [70] 60+, general population No vaccination EUR 16,170/QALY EUR 14,232/QALY
60+, immunocompetent only No vaccination EUR 24,211/QALY EUR 22,255/QALY
Rothberg et al. [42] 60, male No vaccination NA EUR 130,097/QALY
60, female No vaccination NA EUR 81,076/QALY
70, male No vaccination NA EUR 59,794/QALY
70, female No vaccination NA EUR 39,512/QALY
80, male No vaccination NA EUR 173,224/QALY
80, female No vaccination NA EUR 111,779/QALY
Szucs et al. [71] 70-79 No vaccination EUR 13,743/QALY; EUR 3,565/HZ case avoided;
EUR 8,334/PHN case avoided
CHF 15,361/QALY; CHF 3,985/HZ case avoided;
EUR 9,315/PHN case avoided
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Table 6 Economic results of the models evaluating HZ vaccination in the elderly (2010 EUR, German price level) (Continued)
Ultsch et al. [39] 50 No vaccination EUR 37,173/QALY; EUR 1,587/HZ case avoided;
EUR 32,545/PHN case avoided
EUR 30,901/QALY; EUR 1,320/HZ case avoided;
EUR 27,054/PHN case avoided
55 No vaccination EUR 32,480/QALY; EUR 1,518/HZ case avoided;
EUR 26,194/PHN case avoided
EUR 28,244/QALY; EUR 1,320/HZ case avoided;
EUR 22,777/PHN case avoided
60 No vaccination EUR 30,212/QALY; EUR 1,525/HZ case avoided;
EUR 22,337/PHN case avoided
EUR 28,146/QALY; EUR 1,419/HZ case avoided;
EUR 20,809/PHN case avoided
65 No vaccination EUR 30,807/QALY; EUR 1,655/HZ case avoided;
EUR 20,951/PHN case avoided
EUR 29,526/QALY; EUR 1,586/HZ case avoided;
EUR 20,079/PHN case avoided
70 No vaccination EUR 42,190/QALY; EUR 2,732/HZ case avoided;
EUR 22,813/PHN case avoided
EUR 41,942/QALY; EUR 2,716/HZ case avoided;
EUR 22,679/PHN case avoided
75 No vaccination EUR 55,171/QALY; EUR 3,939/HZ case avoided;
EUR 27,396/PHN case avoided
EUR 54,940/QALY; EUR 3,923/HZ case avoided;
EUR 27,281/PHN case avoided
80 No vaccination EUR 92,734/QALY; EUR 9,433/HZ case avoided;
EUR 35,717/PHN case avoided
EUR 92,541/QALY; EUR 9,414/HZ case avoided;
EUR 35,643/PHN case avoided
van Hoek et al. [72] 60 No vaccination EUR 36,302/QALY NA
65 No vaccination EUR 27,747/QALY NA
70 No vaccination EUR 20,589/QALY NA
75 No vaccination EUR 25,211/QALY NA
van Hoek et al. [33] 75 No vaccination 49 % of the simulations below GBP 20,000/QALY
(EUR 26,576/QALY); 96 % of the simulations below
GBP 30,000/QALY (EUR 39,864/QALY)
NA
75 and 2-dose varicella vaccination
of children
No vaccination 50 % of the simulations below GBP 20,000/QALY
(EUR 26,576/QALY); 70 % of the simulations below
GBP 30,000/QALY (EUR 39,864/QALY)
NA
van Lier et al. [41] 60 No vaccination EUR 39,577/QALY EUR 37,638/QALY
65 No vaccination EUR 30,514/QALY EUR 30,514/QALY
70 No vaccination EUR 21,219/QALY EUR 21,219/QALY
75 No vaccination EUR 23,779/QALY EUR 23,779/QALY
80 No vaccination EUR 33,661/QALY EUR 33,661/QALY
HZ herpes zoster; PHN post-herpetic neuralgia; QALY quality-adjusted life-year; NA not applicable
aDepending on the duration of PHN
bAll results from the third-party payer perspective
cDepending on the efficacy and the duration of protection
dDepending on vaccination costs
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Key findings
This systematic review was conducted to summarise the
current state of evidence on the cost-effectiveness of
varicella and HZ vaccination in high-income countries.
To our knowledge, this is the first systematic review cov-
ering cost-effectiveness studies of both varicella and HZ
vaccination. The major findings are outlined below:
Varicella vaccination
– When ignoring the potential impact on HZ and
adopting a health care payer perspective, universal
childhood varicella vaccination was usually a cost-
effective or even cost-saving strategy.
– When switching to a societal perspective, childhood
varicella vaccination was found to be a cost-saving
intervention.
– Vaccination of adolescents was found to be a cost-
effective or cost-saving strategy. However, it remains
unclear if adolescent vaccination is more or less
cost-effective than childhood vaccination due to
inconsistent study results.
– Taking the potential impact on HZ into account, it
is doubtful that childhood varicella vaccination
appears to be cost-effective, at least for several
decades.
HZ vaccination
– In most studies, HZ vaccination was predicted to be
cost-effective or marginally cost-effective.
– When considering both a payer and a societal
perspective, the differences in results between the
two perspectives decreased with increasing age at
vaccination since indirect costs due to sick leave
become less relevant in the elderly population.
– When waning of vaccine-induced immunity was
modelled, cost-effectiveness of HZ vaccination was
highly dependent on the age at vaccination. ICERs
decreased with increasing age at vaccination up to a
certain age, followed by a re-increase of the ICERs
(U-shape) for older ages. Most results suggest that
the optimal age for HZ vaccination is between 60
and 70 years or around 70 years. Furthermore, cost-
effectiveness was dependent on the price of the
vaccine, the duration of protection and the assumed
cost-effectiveness threshold.
Choice of the model
Model choice can influence the results to a great extent
when evaluating the cost-effectiveness of vaccines. In
static models such as decision trees and Markov models
the force of infection is constant over time becauseindividuals were not allowed to interact with each other.
In contrast, dynamic models account for interactions be-
tween individuals and therefore the force of infection de-
pends on the number of susceptible, infectious and
recovered individuals in the population. This is why dy-
namic models can include herd protection effects when
evaluating the impact of vaccines.
More than half of the studies evaluating varicella vac-
cination were based on dynamic models and took herd
protection effects into account. This is an important re-
quirement to assess the impact of different coverage
rates. In several studies the varicella vaccination uptake
was found to be one of the most influential parameters.
Since the force of infection for HZ is constant by nature,
the models assessing only HZ vaccination were kept
static.
Exogenous boosting
The results of studies evaluating the cost-effectiveness of
varicella vaccination were very sensitive to the structural
assumption of allowing for exogenous boosting and its
consequences on HZ incidence. Varicella vaccination
was found to be a cost-effective or cost-saving strategy
as long as the potential impact on HZ incidence was ig-
nored. When taking the potential impact on HZ inci-
dence into account, varicella vaccination was unlikely to
be cost-effective. However, the study by van Hoek et al.
[33] showed that the negative effect on HZ could, at
least partly, be mitigated by the implementation of paral-
lel (temporally limited) HZ vaccination of the elderly.
Indirect costs
Many of the studies on varicella vaccination underlined
the role of indirect costs for the assessment of cost-
effectiveness. When adopting a societal perspective,
savings were largely due to the inclusion of indirect
costs. A previously published review of cost-effectiveness
studies on varicella vaccination [43] found that the indir-
ect costs ranged between 42 and 98 % of the total costs.
On the contrary, results of models evaluating the cost-
effectiveness of HZ vaccination were less sensitive to the
cost perspective adopted because in many scenarios the
target population belonged to age groups with a low
level of labour market participation.
Comparison with previous reviews
We are aware of four previously published systematic re-
views on studies assessing the cost-effectiveness of vari-
cella vaccination [43–46] and one review on studies
examining the cost-effectiveness of HZ vaccination ex-
clusively [47].
Thiry et al. [44] concluded that universal vaccination
of healthy children would generate cost savings to soci-
ety. Although some of the included studies are based on
Damm et al. BMC Public Health  (2015) 15:533 Page 17 of 19dynamic models which could account for herd immunity
effects, only one of the (subsequently added) studies
covered the potential impact on HZ. The results of this
study were only in accordance with the findings of the
other studies when ignoring the impact on HZ. Incorp-
orating the impact on HZ led to highly inefficient
results. Rozenbaum et al. [45] found that routine child-
hood vaccination was a cost-effective or even a cost-
saving strategy as long as the potential impact on HZ
was not considered in the model analyses. Cost-savings
were generally driven by the inclusion of indirect costs
in terms of production losses. Rozenbaum et al. [45] at-
tached great importance to point out that the benefits
provided by the implementation of early-childhood vari-
cella vaccination might be offset due to an increase in
HZ cases in the elderly population. Therefore, they sug-
gested varicella vaccination of high-risk groups such as
susceptible adolescents only, as long as the interactions
between varicella and HZ are not clarified. The conclu-
sions of the review by de Soárez et al. [43] were consist-
ent with those of the two previously published reviews
[44, 45]. Interestingly, Unim et al. [46] concluded that
the results of the reviewed studies undoubtedly support
the introduction of a universal varicella vaccination
programme. Although the authors included two studies
accounting for the potential impact on HZ [31, 32], the
implications of such negative effects of a childhood
varicella vaccination programme were not discussed by
Unim et al. [46]. Hence, the conclusions of this review
are highly disputable. Szucs et al. [47] found that in
almost all studies HZ vaccination was considered as a
cost-effective intervention. Amongst others, age at vac-
cination and vaccination costs had a great impact on the
results. This conclusion is in line with findings of our
review.
One of the strengths of our systematic review is that it
is more comprehensive than previously published review
articles. We included economic evaluations of varicella
vaccination and HZ vaccination while other reviews have
been focused on one of the two vaccines at a time. A
combined assessment of the cost-effectiveness of vari-
cella and HZ vaccination programmes gives consider-
ation to the close relationship of both diseases.
Limitations
Our review was focused on models evaluating varicella
vaccination in children and adolescents as well as HZ
vaccination in the elderly. Studies limited to varicella
vaccination of specific target groups such as health care
workers or pregnant women were excluded because the
current debate is more about whether universal varicella
and HZ vaccination is good value for money; still the
consideration of specific risk groups can affect the over-
all cost-effectiveness. Furthermore, we excluded studieswhich provided no sufficient description of the used
methods (e.g. Hudeckova et al. [48]; Gialoretti et al.
[49]); such studies might provide valid results but could
not be evaluated. In addition, only one literature data-
base (PubMed) was searched, and our review was re-
stricted to articles written in English or German and to
studies reporting results for high-income economies.
It is well known that transferability of results of cost-
effectiveness analyses across countries is usually affected
by a wide range of factors such as variation in disease
epidemiology, clinical practice patterns, unit costs, other
health care characteristics or methodological decisions
[50]. This limitation also holds true for the reviewed
studies. For example, there is a large variability in vac-
cination costs between the included studies. Neverthe-
less, many of the studies reported similar results and
drew consistent conclusions.
Conclusions
Cost-effectiveness of childhood varicella vaccination rests
to a large extent on the interaction between varicella and
HZ. When assuming no exogenous boosting of HZ
immunity, varicella vaccination can be considered as a
cost-effective or a cost-saving strategy. However, this
conclusion needs to be revised when assuming that
exogenous boosting exists because the inclusion of the
effects of exogenous boosting leads to less favourable
results. In this situation, the overall cost-effectiveness
seems to become more favourable when routine child-
hood varicella vaccination is accompanied by the (tem-
porary) implementation of HZ vaccination in the elderly.
As a consequence, clarification on the role of exogenous
boosting is crucial for decision-making regarding vari-
cella vaccine introduction. Cost-effectiveness of HZ
vaccination itself is mainly dependent on the chosen age
at vaccination, the price of the vaccine and the magni-
tude of the cost per QALY threshold.
Based on this review we identified several important
issues that need to be considered when evaluating the
health economic impact of varicella and/or HZ vaccin-
ation. Future economic evaluations of varicella vaccination
should apply a dynamic modelling approach because only
dynamic models can take into account herd protection ef-
fects and the potential impact of varicella vaccination on
HZ incidence due to reduced or absent exogenous boost-
ing. In contrast, when the analysis is focused exclusively
on HZ vaccination, a static model seems to be adequate
since no change in the force of infection in HZ will be
derived from the introduction of HZ vaccination. In
addition, since fatality rates of varicella and HZ are rather
low, we believe using life years gained (LYG) as an out-
come parameter is not sufficient. Thus, we recommend,
as done in most existing studies, to consider health-
related quality of life outcome parameters (e.g. QALYs).
Damm et al. BMC Public Health  (2015) 15:533 Page 18 of 19Moreover, waning of vaccine-induced immunity seems to
play an important role for the impact of both vaccines.
Hence, we recommend addressing this issue already in the
base-case analysis of future evaluations (instead of includ-
ing waning in sensitivity analysis only). Furthermore, when
considering waning of vaccine-induced immunity, the
effects of administering a booster vaccine should be
captured in sensitivity analysis because a booster shot
might have significant impact on the results.
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